Literature DB >> 35058669

Spatial Two-stage Designs for Phase II Clinical Trials.

Seongho Kim1, Weng Kee Wong2.   

Abstract

A common endpoint in a single-arm phase II study is tumor response as a binary variable. Two widely used designs for such a study are Simon's two-stage minimax and optimal designs. The minimax design minimizes the maximal sample size and the optimal design minimizes the expected sample size under the null hypothesis. The optimal design generally has the larger total sample size than the minimax design, but its first stage's sample size is smaller than that of the minimax design. The difference in the total sample size between two types of designs can be large and so both designs can be unappealing to investigators. We develop novel designs that compromise on the two optimality criteria and avoid such occurrences using the spatial information on the first stage's required sample size and the total required sample size. We study properties of these spatial designs and show our proposed designs have advantages over Simon's designs and one of its extensions by Lin and Shih. As applications, we construct spatial designs for real-life studies on patients with Hodgkin disease and another study on effect of head and neck cancer on apnea.

Entities:  

Keywords:  Lin and Shih’s design; Simon’s design; adaptive design; spatial design

Year:  2022        PMID: 35058669      PMCID: PMC8765730          DOI: 10.1016/j.csda.2021.107420

Source DB:  PubMed          Journal:  Comput Stat Data Anal        ISSN: 0167-9473            Impact factor:   1.681


  11 in total

1.  A modification of Simon's optimal design for phase II trials when the criterion is median sample size.

Authors:  J J Hanfelt; R S Slack; E A Gehan
Journal:  Control Clin Trials       Date:  1999-12

2.  Graphical search for two-stage designs for phase II clinical trials.

Authors:  S H Jung; M Carey; K M Kim
Journal:  Control Clin Trials       Date:  2001-08

3.  Optimal three-stage designs for phase II cancer clinical trials.

Authors:  T T Chen
Journal:  Stat Med       Date:  1997-12-15       Impact factor: 2.373

4.  Phase II Two-Stage Single-Arm Clinical Trials for Testing Toxicity Levels.

Authors:  Seongho Kim; Weng Kee Wong
Journal:  Commun Stat Appl Methods       Date:  2019-03-31

5.  Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.

Authors:  Minjung Kwak; Sin-Ho Jung
Journal:  Stat Med       Date:  2013-12-13       Impact factor: 2.373

6.  Extended two-stage adaptive designs with three target responses for phase II clinical trials.

Authors:  Seongho Kim; Weng Kee Wong
Journal:  Stat Methods Med Res       Date:  2017-05-23       Impact factor: 3.021

7.  An optimal three-stage design for phase II clinical trials.

Authors:  L G Ensign; E A Gehan; D S Kamen; P F Thall
Journal:  Stat Med       Date:  1994-09-15       Impact factor: 2.373

8.  Optimal sequential enrichment designs for phase II clinical trials.

Authors:  Yong Zang; Ying Yuan
Journal:  Stat Med       Date:  2016-09-19       Impact factor: 2.373

9.  Admissible two-stage designs for phase II cancer clinical trials.

Authors:  Sin-Ho Jung; Taiyeong Lee; KyungMann Kim; Stephen L George
Journal:  Stat Med       Date:  2004-02-28       Impact factor: 2.373

10.  Adaptive two-stage designs for single-arm phase IIA cancer clinical trials.

Authors:  Yong Lin; Weichung J Shih
Journal:  Biometrics       Date:  2004-06       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.